<DOC>
	<DOCNO>NCT00303316</DOCNO>
	<brief_summary>This study ass antibody persistence investigational vaccine immune response safety booster dose PENTAXIM™ vaccine 18 months-old toddler participate earlier study order determine still protect receive booster dose D , T , IPV , pertussis Hib vaccine also assess quality induce immune memory response booster dose vaccine primary series . Primary Objective : To describe antibody persistence 18 month age booster effect dose PENTAXIM™ immunogenicity . Secondary objective : To describe safety profile booster dose PENTAXIM™ vaccine group define vaccine receive primary series .</brief_summary>
	<brief_title>Immunogenicity Study Antibody Persistence Booster Effect PENTAXIM™ 18 Months Healthy Argentinean Infants</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Toddler 18 month age ( range : 510 day 578 day age inclusive ) Participated study A3L02 ( NCT00831311 ) complete threedose primary series either diphtheria , tetanus , pertussis ( 2component acellular ) , recombinant Hepatitis B Hansenula poliomyelitis vaccine adsorb , Haemophilus influenzae type b vaccine , conjugate tetanus protein ( DTaPIPVHBPRP~T ) PENTAXIM™ ENGERIX B® PEDIATRICO 2 , 4 , 6 month age Written inform consent form sign least one parent legal representative independent witness Able attend schedule visit comply trial procedure . Participation another clinical trial four week precede trial vaccination Planned participation another clinical trial present trial period Congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month longterm systemic corticosteroid therapy Systemic hypersensitivity vaccine component history lifethreatening reaction vaccine contain substance Chronic illness stage could interfere trial conduct completion Blood bloodderived product receive last six month Any vaccination four week precede trial Vaccination vaccine contain diphtheria , tetanus , pertussis , Haemophilus influenzae type b , polio , hepatitis B antigen , since end primary series History document diphtheria , tetanus , pertussis , Haemophilus influenzae type b , polio , hepatitis B infection ( ) ( confirm either clinically , serologically , microbiologically ) Thrombocytopenia bleed disorder contraindicate intramuscular vaccination History seizures Fever ( axillary temperature ≥37.4°C equivalent rectal temperature ≥38.0°C ) acute illness day inclusion Known contraindication vaccination pertussis vaccine : Encephalopathy ; Inconsolable cry &gt; 3 hour within 48 hour follow vaccine injection Hypotonic hyporesponsive episode within 48 hour follow vaccine injection Seizures without fever within three day follow vaccine injection Axillary temperature &gt; 39.4°C equivalent rectal temperature &gt; 40.0°C within 48 hour follow vaccine injection .</criteria>
	<gender>All</gender>
	<minimum_age>510 Days</minimum_age>
	<maximum_age>578 Days</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Pertussis</keyword>
	<keyword>whooping cough</keyword>
	<keyword>Haemophilus influenzae type b</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Poliomyelitis</keyword>
</DOC>